# Current Treatment Approaches to Breast Cancer

2

Manzoor Ahmad Mir and Abrar Yousuf Mir

## 2.1 Introduction

The treatment of breast carcinoma is comprehensive. Early detection of breast cancer has a lesser risk of progression, a minor rate of reappearance, and a high probability of survival (McPhail et al. 2015). Timely detected breast carcinoma may be treated with local and systemic approaches (Anampa et al. 2015). However, invading, aggressive breast tumor survival rates often remain less (García Rodríguez et al. 2010; Mehraj et al. 2021a, 2021b). Treatment for malignancy necessitates a planned, holistic approach in which competent onco-surgeons and professional workers coordinate within a functional infrastructure to run the important therapies while decreasing the patient's economic and logistical constraints. These days, various options are available for the treatment of breast tumors, including radiotherapy, chemical therapy, surgical methods, hormonal therapy, immunotherapy, targeted therapy, and, novel, genetic therapy. The mortality graph due to breast cancer is flattening due to progression in screening, diagnosis, and treatment. Most female patients receive adjuvant systemic therapy because it has been shown to improve survival rates and provide better results, and molecular profiling to personalize cure based on the threat is now a medical reality for patients with HR-positive carcinoma. Breast-conserving surgeries with radiation therapy or mastectomy are options for most females with low-grade breast tumors. Fractional mastectomy, lumpectomy, quadrantectomy, and local excision are some of the options for breast-conserving surgery. Breast conservation therapy has been practiced for more than two decades, with these techniques followed by five to seven weeks of phototherapy. Breast cancer is a divergent disease at the molecular level, molecular trait includes

M. A. Mir (✉) · A. Y. Mir
Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar, J&K, India
e-mail: drmanzoor@kashmiruniversity.ac.in



M. A. Mir (ed.), *Therapeutic Potential of Cell Cycle Kinases in Breast Cancer*,
https://doi.org/10.1007/978-981-19-8911-7_2

activation of HER2 which is encoded by ERBB2, activation of hormone receptors (ER and PR), and mutations in BRCA genes. So, breast cancer diagnosis and treatment necessitate a multidisciplinary approach involving several subspecialties. Diagnostic imaging work-up and biopsy are critical in initiating a diagnosis and influencing surgical choices on primary tumor management, axillary staging, and the treatment sequence (Qayoom et al. 2022, p. 1122). After a breast tumor diagnosis is made, the degree of the illness is accessed, which directs whether systemic neoadjuvant therapy is necessary or not. Breast cancer in advanced stage IV is considered incurable unless there is a reason for palliative resection of the primary tumor, stage four is treated solely with systemic therapy. The death rate of breast tumors has lowered in the last few decades due to progression in chemotherapy for handling breast cancer (Osborne 1998; Sofi et al. 2022). In addition, the efficiency of biological therapies like as anti-HER2 monoclonal antibodies established the opportunity and significance of the molecularly targeted method in BC therapy (Gianni et al. 2011). TNBC which can invade other parts of the body is still a grave illness with few therapeutic options. The biological processes underlying the diverse treatment response in BC have been better understood in recent years. Tamoxifen and other endocrine medications have transformed breast cancer management, resulting in significant reductions in cancer-related deaths.

## 2.2 Breast Cancer Radiation Therapy

Radiation therapy is a cancer-killing and tumor-shrinking treatment that employs high-energy radiation. Elevated energy radiation destroys cellular genetic pools, preventing them from further growth and expansion (Jackson and Bartek 2009; Mehraj et al. 2021a, 2021b). Even though radiation damages both cancerous and non-cancerous cells, the main objective of radiotherapy is to significantly augment the radiation amount to tumor cells while dropping risks to healthy cells located close to carcinoma cells or in their radiation path. Cancer cells generally are not as effective as normal cells in repairing radiation damage, which leads to the death of differing cancer cells (Begg et al. 2011). Radiotherapy plays a key function in the management of both "non-invasive and invasive BC". In both therapeutic and palliative care settings, radiation therapy is beneficial in the management of breast malignancy (Bese et al. 2008). Following "breast-conserving surgery" radiation of the breast yields oncologic results comparable to those of a mastectomy in early illness (Fisher et al. 2002; Veronesi et al. 2002). In individuals with advanced-stage cancer, adjuvant locoregional radiation to the breast wall and nearby lymphatic nodes lowers the risk of local and distant recurrence with a benefit to disease-specific overall survival (Braunstein et al. 2017). This advantage is enhanced by risk factors including node positive, adolescence, triple-negative molecular markers, high-grade cancer as well as lymph vascular invasion are present (Vrieling et al. 2017; Mir et al. 2020). Once radiation exposure levels are raised to include regional disease, the danger of toxicity, particularly to the "lungs and heart" rises. Providing radiation to patients with MBC is beneficial in several cases (McGale et al. 2014).

When surgical resection is not an option, palliative radiation can help with local control in cases of dermal recurrence or localized disease. More exact and homogeneous radiation therapy can be provided with advances in CT image analysis, simulation, patient monitoring, and delivery methods. After BCT, radiotherapy options include "hypo-fractionated, entire breast radiation, accelerated restricted breast radiation with external beam treatment beam therapy." Radiation can be delivered to the tumor spot mainly in two ways. External beam radiation from outside the body is transmitted to the tumor site by targeting high-energy rays (protons or particle radiation and photons). This is the most commonly used approach in clinical settings.

### 2.2.1 External Beam Radiation Therapy

Unless systemic chemotherapy is administered, teletherapy usually starts three to six weeks after surgical treatment. The simulation process is the first step in cancer treatment. Each patient receives a unique "breast boards, wing boards" or set of cradles or molds that can be customized. This ensures that the sufferer is in a consistent state for each treatment. Patients are usually positioned supine, with their torsos inclined 10–15 degrees. The shoulder is outwardly rotated and the ipsilateral arm is grabbed at about 100–120 degrees. At this moment, radio opaque wires are positioned as well as managed to secure beside the operational scars. The treatment field borders are then defined by the radiation oncologist to include breast target and if necessary, nearby lymph nodes, the stimulated CT is carried out. The iso-center is selected then patient's skin is marked with daily set-up marks. Treatment planning in three dimensions is carried out. The volumes of treatment and key structures are determined and defined. The best beam configurations are selected.

Tangential fields encompassing the most anterior thorax are commonly used for early-stage BC. "Level I and II lymph node chains" are examples of these fields. Though most of the levels I and II axillary nodes are to be included, although special attention must be paid to the tangent field margins particularly the contact between the cranial and posterior chest wall (Schlembach et al. 2001). Radio-therapy to the supraclavicular fossa with or without posterior axillary boost may be beneficial for patients who have un-dissected nodes, or one to more lymph node metastases, or one to three positive nodes. 4–6 MV-photon energy is typically employed to treat the breast and lymph nodes. Whole-breast radiation therapies are given five days a week, with a total dose of about "50 Gy" administrated in 25–28 fragments. Electrons are commonly used in the boost treatment. At 1.8–2 Gy per fraction, the "lumpectomy cavity" is strengthened in favor of additional 10–16 Gy. "Intensity-modulated radiation therapy (IMRT) or planning IMRT" for treatment of breast has been developed due to discoveries in radiation therapy design and delivery systems. With IMRT, the dosage of the "contralateral breast" is lowered (Borghero et al. 2007). In comparison to standard radiotherapy, it has been shown that planning IMRT can produce more uniform plans with very few hot spots (Bamett et al. 2009) and (Herrick et al. 2008).

## 2.3 Breast Brachytherapy

"Breast brachy-therapy" was once used as "boost" after outside entire breast radiation therapy for treating the lumpectomy cavity. Utilization of "accelerated partial breast irradiation (APBI)" has now been adopted by various clinics either with various applications such as Contura multi-lumen balloon, SAVI, MammoSite balloon or with interstitial needle implants, or 3D conformal external "radio-therapy after breast-conserving surgery" as the sole mode for radiation treatment. Higher dosages of radiation per fraction deposited on the tumor bed by irradiating smaller volume. When particularly in comparison to daily whole breast external beam radiotherapy, this dramatically reduces treatment times and the patient's travel time. Even after breast-conserving surgery, "interstitial breast brachytherapy" was used efficiently for ten years. Proxima Therapeutics' MammoSite* balloon catheter has been sanctioned by the FDA in 2002 for intra-cavitary sufficient dosage rate of breast brachytherapy. A potential multi-center study assesses efficacy of the "MammoSite® balloon catheter" registered 70 patients in the beginning. Following that, only light to medium self-limited side effects were found in 43 patients who were eligible for the therapy (Keisch et al. 2003; Mehraj et al. 2021a, 2021b). Recently, the "American Society of Breast Surgeon" released the outcome of a registration study consisting of 1440-women who were allowed to treat with the "MammoSite® catheter after breast-conserving surgery." Frequency of "Ipsilateral BC as well as axillary rates were 2.15 percent and 0.36 percent" including both, after three years (Nelson et al. 2009). The balloon catheter has the benefits of being simpler to insert into the cavity, quite repeatable placement, and enhanced care comfort. It has the most widespread use as well as a prolonged track record.

One of the most recent brachytherapy devices in the market is the ClearPath™ multi-catheter device. The catheter is inserted via a single access point, but there is no need for a separate radiation source. In comparison to a single catheter system, using a multi-catheter hybrid can decrease dosage of normal breast cells and skin (Dickler 2009). The "SAVI device" such as single-entry, multi-catheter applicator that enables "radiation oncologist" to preferentially head-on radiation through up to "11 catheter channels" enabling additional customized manipulation of the iso-dose partitions is another latest change to the internal radiotherapy option. The equipment consists of collection of extensible catheters which are arranged throughout the central-lumen. This device attempts to combine the benefits of "interstitial brachytherapy" consisting the convenience of a single-entry device (Scanderbeg et al. 2009).

## 2.4 Breast Cancer Chemotherapies

Chemotherapy is the use of anti-cancer medications to treat tumor cells (Fig. 2.1). Breast cancer treatment will be depending on a number of variables including overall health, medical history, age (including whether or not menstruation is present), type and stage of cancer, and sensitivity to prescribed drugs and protocols. Chemotherapy choices are typically given in cycles: a treatment for a pre-determined amount of




**Fig. 2.1** Different kinds of chemo-therapeutic factors are used in the diagnosis of breast carcinoma

time followed by recovery phase and then another treatment. Before surgery, chemotherapy can be used to reduce the size of the tumor and, in some situations, allow for breast-conserving surgery rather than a mastectomy. It is routinely given after surgery and is sometimes given in a "dose-dense" manner.

### 2.4.1 Adjuvant Chemotherapy

For high-risk patients systematic chemotherapies are recommended. Innumerable number of chemotherapies are available such as anthracycline and a taxane. "Dox and cyclophosphamide" for 4-cycles accompanied by paclitaxel for 4-cycles (AC-T) is an effective treatment regimen in the United States. AC-T given in a constant dose (cd) manner after every two weeks with growth factor assistance after the chemotherapy cycle outperforms the previous schedule of every three weeks (Citron et al. 2003). Other optimum AC schedule after taxane involves weekly 12-week paclitaxel or 4-cycle docetaxel every three weeks (Sparano et al. 2008) (Table 2.1). DAC, docetaxel with AC, is also another common option, but not more advanced than the above treatments and docetaxel is more toxic than paclitaxel, and particularly has increased rates of febrile neutropenia (Swain et al. 2013; Mehraj et al. 2021a, 2021b).

The advantage of adjuvant chemotherapy was shown by meta-analyses to reduce recurring and breast cancer death rates in those suffering from HR negative BC with

**Table 2.1** Breast cancer adjuvant chemotherapy treatment regimens

| Regimen | Dosage and schedule | Repetition | Cycles |
|---|---|---|---|
| *Dose-dense* | | | |
| Doxorubicin | 60 mg/m$^2$ IV day 1 | Every 14 days | 4 |
| Cyclophosphamide | 600 mg/m$^2$ IV day 1 | | |
| After that | | | |
| Paclitaxel | 175 mg/m$^2$ IV day 1 | Every 14 days | 4 |
| *AC ⇒ Taxol (T)* | | | |
| Doxorubicin | 60 mg/m$^2$ IV day 1 | Every 21 days | 4 |
| Cyclophosphamide | 600 mg/m$^2$ IV day 1 | Every 21 days | 4 |
| After that | | | |
| Paclitaxel | 175 mg/m$^2$ IV day 1 | Every 21 days | 4 |

a higher level of benefit (Peto et al. 2012). Berry et al. have analyzed the data from cancer and leukemia Group B Also "US Breast Cancer Intergroup reduced 21–25 percent risk rate of individuals with HR-BC in comparison to 8-12 percent having HR+BC (Berry et al. 2006). Oncotype DX estimates chemotherapy benefits for patients with HR+ and node-negative BC. Individuals with elevated "Onco-type re-occurrence scores ≥31" leading to a significant decrease in recurrence risk with chemo-therapy (relative risk—0.26), on the other hand, those with poor scores receive little, whether any, advantage from chemotherapy (Paik et al. 2006). Although worries about anthracycline-associated cardiotoxicity or leukemogenic possibilities exist, anthracycline-carrying adjuvant therapy treatments had been utilized in the early-stage diagnosis of BC. "*Anthracycline*-based regimens" related to per annum risk of cardiopulmonary arrest of "0.08″ percent/year, in the 2000 "Early Breast Cancer Trialists' Collaborative Group (EBCTCG)" summary, compared to 0.06 percent a year in diagnosis of individuals with "non-anthracycline-based regimens." 9735 studies in US Oncology validated TC (docetaxel/cyclophosphamide) a feasible treatment for women with "early-stage breast cancer" particularly for those who are at a significant risk of cardiopathy or require treatment only for twelve-weeks (Jones et al. 2009). In this trial, 1016 females with treatable "breast cancer (stages I–III)" were randomly assigned phases of TC or 4-phases of "standard-dose AC (Adriamycin/cyclophosphamide)." Both DFS (81% vs 75%) and OS (87% vs 82%) were higher in the TC group after an average duration 7 years. Additionally, a meta-analysis comparing "anthracycline-based with non-anthracycline-based regimens" in 6564 females with primary-stage BC found that anthracycline treatment was only beneficial in individuals with HER2-positive cancer (Gennari et al. 2008). Topoisomerase IIa, the gene (TOP2A) which is situated after "HER2 gene on chromosome 17" is inhibited by anthracyclines in a biological sense. In around 35% of HER2 over-expressing breast tumors, TOP2A is co-amplified (Press et al. 2011).

TAILORx (Trial-Assigning-Individualized-Options-for-Treatment) randomly selected individuals suffering via Onco-type, incidence scores of 11–25 either with hormone therapy alone or hormone therapy in conjunction with chemotherapy.

Sufferers in this given cohort receive "anthracycline-containing or anthracycline-sparing" chemotherapy. Hormone therapy alone would be sufficient in sufferers with reduced Onco-type repetition scores, particularly those under 11.

### 2.4.2 Neo-Adjuvant Chemotherapy

Initially, neo-adjuvant chemotherapy was utilized to produce regionally advanced, uncurable resectable BC. NAC has lately been utilized to "downstage illness in the breast and axilla in treatable tumors" to allow breast conservation, and, in certain cases, to minimize axillary lymph node dissection. Various randomized trials have looked at the oncologic protection and survival rates of NAC (Van der Hage et al. 2001; Fisher et al. 1998). A systemic review of diagnosed individuals with "NAC vs surgery" after chemo-therapy found no significant distinction viability or loco-regional recurrence with "NAC," but 17% reduced rate of mastectomy in those receiving NAC (Mieog et al. 2007). Since a larger number of women involved in these trials were candidates for BCT at the time of diagnosis and therefore could not benefit from NAC, 17% is a conservative estimate. NAC is more likely to permit BCT in women with uni-centric malignity that are enormous in comparison to the breast size, as well as who have "HER2+" or triple-negative breast cancers. In clinically node-negative females, the use of NAC dramatically lowers the risk of axillary metastases. Higher rates of PCR in the breast and axilla have been observed after NAC in response to more effective systemic therapies. In three prospective randomized clinical studies, the effectiveness of sentinel node biopsy performed after NAC in patients with nodal metastases was examined. According to the "ACOSOG Z1071 and SENTINA studies, false-negative rates" are less than 10%, when is equal to what is acceptable for sentinel nodal biopsy in the fundamental surgical context. In a randomized trial done by "Memorial Sloan Kettering Cancer Center" 288 patients with nodal metastases who were clinically node-negative after NAC had a nodal pCR in 48% of the cases (Mamtani et al. 2016).

## 2.5 Breast Cancer Endocrine Therapy

The principal regulators of breast tissue development and differentiation are estrogen and progesterone. The ovaries are the primary source of both steroid hormones. They act on cells by attaching to "activating nuclear receptors" called "estrogen-receptors (ERs)" and "progesterone receptors (PRs)." These "receptors" demonstrate membrane-localized as well as transcriptional signaling activity once activated. Two of the most common ERs are ERα and ERβ. ERα is expressed in 70% of breast tumors; however, ERβ is poorly identified (Bland and Copeland 2009).

George T. Beatson was the first to notice the potential significance of estrogen in breast tissue, seeing that oophorectomy in rabbits led to lactation loss. Based on this finding, Beatson conducted an "oophorectomy" on a premenopausal woman with an unresectable breast carcinoma on June 15, 1895. She was cured and lived for another

four years. Beatson's early work established the groundwork for hormone therapy. Most cancers that screened positive for estrogen or progesterone receptors respond well to endocrine therapy. Endocrine therapy could be used for 5–10 years, and probably much longer, in some cases. The main types of endocrine therapies include—tamoxifen and AIs.

### 2.5.1 Tamoxifen

There is a strong evidence to support the use of Tamoxifen as an adjuvant endocrine treatment for early-stages (Jankowitz and Davidson 2013). A nonsteroidal antiestrogen Tamoxifen was licensed by the US FDA in the 1970s as a hormonal therapy for postmenopausal women with metastatic breast cancer (mBC) (Fig. 2.2). According to guidelines from the "National Institutes of Health Consensus Conference on Breast Cancer Chemotherapy 1985" tamoxifen's use was extended to the "adjuvant setting with the treatment of postmenopausal women with node+ and ER+ tumors." Since 1958, randomized controlled studies have been carried out by the "National Surgical Adjuvant Breast and Bowel Project (NSABP)" to examine various aspects of adjuvant and surgical therapy (Band 2010). 2644 patients with node-negative, receptor-positive cancer underwent surgery and they are randomly assigned to receive either 5-years of Tamoxifen or *Placebo* in NSABP B-14 trail (Mamounas 2003). When tamoxifen was used instead of a placebo, the trial proved a




**Fig. 2.2** Mechanism of action of the Tamoxifen: Tamoxifen blocks the action of estrogens binding to the "hormonal receptors" on the cancer cells; thereby estrogen is no longer able to bind to these receptors, due to which the mammary epithelium no longer functions as an estrogen receptor and proliferation of cancer cells is gradually slowed or stopped due to a lack of estrogen

remarkable improvement in "disease-free survival (DFS)." In addition, 194 RCT (randomized clinical trials) evaluated by "Early Breast Cancer Trialists' Collaborative Group (EBCTCG)" also discovered that adjuvant-tamoxifen therapy for 5-years in individuals with ER+ BC lowered breast tumor death rates by 31% and was considered highly efficient than 1 or 2 years of tamoxifen therapy. The EBCTCG found that 5-years of "adjuvant tamoxifen" in women with ER+ BC remarkably decreased relapse by one-third over the first ten years and decreased BC death rate by one-third over the first fifteen years in a follow-up meta-analysis. Tamoxifen treatment for five years possesses backbone of "adjuvant-hormone therapy" particularly for pre-menopausal women having BC, due to a slew of good research (Jankowitz and Davidson 2013).

### 2.5.2 Aromatase Inhibitors

Because ovarian tissue no longer produces estrogen, post-menopausal women instead use the enzyme aromatase to manufacture it predominantly from non-glandular sources. In addition to being separated from BC cells, aromatase has also been found in a number of other organs such as muscle, sub-cutaneous fat, and the liver (Bland and Copeland 2009). Because estrogen suppression has been so successful in the past, "aromatase inhibition" has received a lot of attention as a BC treatment option (Table 2.2).

Aromatase inhibitors (AIs) were efficient in the treatment of BC for the first two generations, but they had substantial adverse effects since they blocked other androgenic hormones like "cortisol and aldosterone." AIs third generation possesses greater aromatase selectivity so it is classified either as "steroidal (type I) or nonsteroidal (type II)." Non-steroidal impediment are reversible competitive inhibitors, whereas steroidal inhibitors irreversibly decrease enzyme activity. Women with metastatic BC were the first to be examined using third-generation AIs. When the efficacy of AI therapy in metastatic BC was discovered, the focus switched to its application in adjuvant settings. Several tamoxifen-treated patients had recurrences due to medication resistance or experienced detrimental effect including endometrial malignancy as well as "venous thromboembolic disorder." Alone in the *Arimidex, Tamoxifen*, or in Combination (ATAC) studies, 9366 post-menopausal women are localized with BC, were given *anastrozole* or *tamoxifen* for 5 years (Howell et al. 2005). *Anastrozole* substantially improved DFS (575 versus 651 occurrences; "hazard ratio = 0.87; confidence interval of 95 percent [CI] 0.78–0.97; $P = 0.01$)" following an average duration of 68 months. Patients on *anastrozole* had decreased threat of "venous thromboembolic" occurrences, endometrial malignancy, and "hot flashes" (Howell et al. 2005). Letrozole, a second type II AI, and tamoxifen were compared against one another in the "Breast International Group (BIG) 1-98 Collaborative Group" investigation. 8010 participants in the double-blind phase 3 trial were randomly assigned to "*tamoxifen* upto 5 years, *letrozole* for 5 years, *tamoxifen* for 2 years followed by *letrozole*, or *letrozole* for 2 years followed by tamoxifen." The original trial compared the two

**Table 2.2** Clinical trials of aromatase inhibitors

| Trial id or name | Treatment plans | No. of individuals | Endpoints | Results |
|---|---|---|---|---|
| ATAC, 2005 | Five years of 1-milligram anastrozole vs. 20-mg tamoxifen vs. combination therapy | 9366 | DFS, OS, safety, the incidence of contralateral breast cancer, and time to distant recurrence | Anastrozole significantly extended DFS. |
| BIG 1-98, 2006 | Five years of 20-milligram tamoxifen vs. 5 years of 2.5-mg letrozole vs. 2 years of 20-mg tamoxifen following 3 years of 2.5-mg letrozole vs. 2 years of 2.5-mg letrozole following 3 years of 20-mg tamoxifen | 8010 | DFS, systemic DFS, OS, time to distant recurrence. | Letrozole improved DFS, decreased distant recurrences, and extended the time to distant metastasis. |
| FACE, 2017 | 5 years of 2.5-mg letrozole vs. 5 years of 1-mg anastrozole | 4136 | Safety and effectiveness | 5 year DFS rate was 84.9% for letrozole vs. 82.9% for anastrozole. |
| EBCTCG, 2015 | 5 years of an AI (group 1) vs. 5 years of tamoxifen (group 2) vs. 2–3 years of tamoxifen following AI to year 5(group 3) vs. 2–3 years of an AI following tamoxifen to year 5 (group 4) | 31,920 | Recurrence, BC mortality, death without recurrence, and all-cause mortality | Compared to tamoxifen, AIs lowered recurrence rates by about 30%. |

groups assigned to receive tamoxifen, letrozole has a greater 5-year survival rate compared to the tamoxifen arm"84.0 percent and 81.4 percent, respectively." According to this study "Thromboembolism, endometrial cancer, and vaginal bleeding were all common in the *tamoxifen* arm (Thürlimann 2006).

Based on such trials, as well as on the 51-month to check out "BIG 1-98 trial" FDA recommended "*anastrozole* and *letrozole"* for hormone-sensitive early-stage BC as initial adjuvant therapy. "*Femara* Versus *Anastrozole* Clinical Evaluation (FACE)" a recently randomized phase-3-trial, examined the effectiveness and safety of *anastrozole* plus *letrozole* (Smith et al. 2017). Letrozole has been shown in earlier pharmacotherapeutic studies to block estradiol more effectively, but the FACE study that letrozole was not significantly safer or more effective than anastrozole in 4136 postmenopausal women with hormone receptor-positive and node-positive BC (Smith et al. 2017). Meta-analysis of randomized trials contrasting ALs and tamoxifen in early BC was also carried out by EBCTCG, and results were compared after 31,920 post-menopausal women with early BC and ER+ were divided into several therapeutic groups. The different sub-groups were; group 1: 5 years of AI, group 2: 5 years of *tamoxifen*, group 4: 2–3 years of an AI followed by *tamoxifen* for the total of 5 years. A five-year comparison between AI and changeover 2–3 years of *tamoxifen strategy subsequently* followed by AI for five years, indicated a reduction in recurrence in the "first year" of the AI-group, however, this advantage lost, when simultaneously taking both groups as AI.

### 2.5.3 Switching Trails in Endocrine Therapy

After two-three years of *tamoxifen*, AIs were also examined as a follow-up therapy. In conjunction with the *Arimidex-Nolvadex* 95, The (ABCSG) group "Austrian-Breast and Colorectal Cancer Study Group' trial 8" analyzed effectiveness of converting "*anastrozole"* for three years besides the adjuvant *tamoxifen* treatment for 2-years (Jakesz et al. 2005). 3224 post-menopausal women having HR+ BC, who had been taking tamoxifen for 2 years are randomly assigned to have "1 mg *Anastrozole*, 20 mg *Tamoxifen*, or 30 mg *Tamoxifen*" have been set up by investigators in the course of study. 40% depletion was observed in average duration of 28-months "67 *anastrozole* versus 110 *tamoxifen* events; 0.60; 95% CI 0.44–0.81; $P = 0.0009$" in threat for an event with anastrozole (Jakesz 2005). The "Intergroup *Exemestane* Study (IES) examined-*Exemestane*" which is a type I-AI, in the adjuvant setting after *tamoxifen* therapy (Coombes 2004). The researchers evaluated 4742 "post-menopausal women with ER+ or ER unknown" BC, which after 2–3 years of adjuvant-*tamoxifen*, had no disease signs and had been randomly assigned for the entire five years for either exemestane or *tamoxifen* therapy. They discovered a 32% risk decline in the *exemestane* group after an average duration of 30.6-months, leading to a remarkable benefit, "DFS of 4.7 percent at 3-years" following randomization. These switching studies demonstrated that using AIs and *tamoxifen* sequentially offered significant benefits.

The Netherlands-based "analysis on the Duration of Extended Adjuvant *Letrozole* (IDEAL)" experiments randomized participants to 2.5–5 years of "*letrozole"* following 5 years of endocrine therapy. However, about 74% participants have completed "letrozole" for 2.5 years and just 57% have completed *letrozole* for 5 years (Blok et al. 2016).

## 2.6 Targeted Therapies in the Treatment of Breast Carcinoma

"Targeted therapies" for BC are utilized to diagnose individuals to whom which "BC cells" have an aberrant growth pattern due to the overexpression of particular distinctive proteins on their cell surface. Antibodies, which act identically to the human immune system, are primarily utilized as BC targeted therapy. Targeting up-regulation of the "HER2 protein" on the periphery of the breast cancerous cells is the most productive "breast cancer targeted therapy" available today (Fig. 2.3). There are currently some extensively used BC targeted therapies that are successful in blocking many molecular pathways (Table 2.3) such as *Trastuzumab*, also known as Herceptin, which inhibits cancer cells from receiving signals that tell them to grow (Giordano et al. 2014). *Pertuzumab*, also known as perjeta, works by blocking the signals that cancer cells use to proliferate (Giordano et al. 2014; Baselga et al. 2012). *Bevacizumab,* also known as *Avastin*, stops cancer cells from growing new blood capillaries that supply them oxygen, as well as nutrients (Gianni et al. 2013) and so on.




**Fig. 2.3** Mechanism of action of targeted therapy in the treatment of breast cancer

**Table 2.3** Targeted therapies clinical trails

| Agent | Clinical trial id | Phase | Recruitment status |
|---|---|---|---|
| Trastuzumab | NCT00004067 | III | Complete |
| | NCT00045032 | III | Complete |
| Pertuzumab | NCT00567190 | III | Complete |
| | NCT00545688 | II | Complete |
| T-DM1 | NCT00829166 | III | Complete |
| | NCT01772472 | III | Active, not recruiting |

### 2.6.1 HER2+ Malignant Tumor of Breast

Human-epidermal-growth-receptor positive is an ErbB family "tyrosine kinase receptor" that is involved in pathways of cell signaling that promote cell proliferation, differentiation, and apoptotic suppression (García-Aranda and Redondo 2017). HER2, the most often differentially expressed "receptor in breast cancer" is highly expressed in around 15% cases of BCs, resulting in dysregulated cell proliferation (García-Aranda and Redondo 2017; Masoud and Pagès 2017). Because HER2 powerfully triggers tumor-growth-related downstream pathways, its expression levels are closely related to breast cancer metastasis and prognosis. "HER2" has been used as a biological target for discovery of novel therapeutics for these reasons throughout the last 20 years. Anti-HER2 therapy has enhanced survival in HER2 + breast cancers, even though they develop quickly and are more aggressive than other forms (Nami and Wang 2017) and (Mir et al. 2020).

### 2.6.2 Trastuzumab

Trastuzumab or Herceptin is the cornerstone of HER2+ BC treatment. It is the first FDA-approved humanized immunoglobulin G1kappa monoclonal antibody (mAb) which has been found to significantly increase DFS and OS in numerous clinical studies (Masoud and Pagès 2017). The "B-31 National Surgical Adjuvant Breast and Bowel" (NCT00004067) study contrasted a 4-cycle AC chemotherapy strategy, followed by weekly 12-week *paclitaxel*, against the same chemo-therapy strategy "plus 1 year of *trastuzumab*" beginning on the Ist-day of the therapy with "*paclitaxel*" (Romond et al. 2005). Participants present in "*trastuzumab* group had an elevated DFS rate than those found in the control after an average duration of two years. Furthermore, the possibility of mortality was lowered by nearly a third (Romond et al. 2005).

The trial HERA (NCT00045032) enrolled women who had undergone surgery and had finished 04 rounds of "adjuvant chemotherapy." The trial compared was *trastuzumab* ($n = 1693$) with an additional year or two years of *trastuzumab* ($n = 1694$) once this regimen was completed. In combined 1–2 year *trastuzumab* cohort exhibited greater value of "DFS" than the examination groups after an

average duration of 1 year, with "127 DFS" occurrences in the "*trastuzumb"* cohort in comparison with 220 in the "observation cohort" (Piccart-Gebhart et al. 2005).

In these trails, the use of "adjuvant *trastuzumab plus anthracycline*-based regimens" (such as *doxorubicin*) was linked to high risk of cardiopulmonary arrest in these trials (Romond et al. 2005) and (Piccart-Gebhart et al. 2005). Therefore, the BCIRG 006 research looked into a trastuzumab-based non-anthracycline regimen (group 3) and compared three groups: Every three weeks, four rounds of "doxorubicin and cyclophosphamide were subsequently followed by four doses of docetaxel (AC-T) (group 1)" "AC-T followed by one year of trastuzumab beginning with the first-docetaxel dose (group 2), as well as 6 docetaxel rounds in combination with carboplatin and "contemporaneous *trastuzumab* (TCH)" followed-by 34 weeks of "*trastuzumab."* When compared to normal AC-T therapy, *trastuzumab*-groups demonstrated improvements in DFS as well as in OS. Additionally, AC-T plus *trastuzumab* group had a "5-year DFS" value of 84% and 92% OS value, both with P-value <0.001.TCH had a "five-year DFS" rate of 81% as well as OS rate of 91%, with a P-value of 0.04 (Slamon 2011). Regardless of ER status, clinical studies with adjuvant trastuzumab have shown clinically substantial progression in DFS. In addition, clinically substantial improvements in the OS were shown in the B31 and HERA studies.

### 2.6.3 Pertuzumab

The monoclonal antibody (mAb), *Pertuzumab, which is recombinantly humanized,* binds to HER2 and inhibits its dimerizing with other HER-receptors (Franklin et al. 2004). Since "*pertuzumab"* interacts with HER2 at a distinct-epitope than "*trastuzumab*" and stimulates "antibody-dependent cell-mediated cytotoxicity" via complementary pathways, when used jointly, *pertuzumab* and *trastuzumab* exhibit stronger antitumor efficacy than either therapy alone (Franklin et al. 2004). To treat individuals with HER2+ mBC, pertuzumab is used in conjunction with *trastuzumab* and *docetaxel*. It is also utilized as a neo-adjuvant treatment for early HER2 +,"advanced, or inflammatory BC," in addition being used in conjunction with *trastuzumab plus* and chemotherapy for adjuvant therapy of HER2+ early BC with an extreme chance of re-occurrence. *Pertuzumab's* effectiveness and safety have been studied in some clinical trials. *Pertuzumab* with "*trastuzumab* plus *docetaxel"* as contrast to a *placebo* and "*trastuzumab* with *docetaxel"* in the CLEOPATRA phase 3 trial (NCT00567190) to treat mBC (Baselga et al. 2012). The *pertuzumab* group showed a clinically meaningful improvement in PFS. The phase 2 trial of Neosphere (NCT00545688) compared four groups to check the efficacy of "*pertuzumab*: *trastuzumab* with *docetaxel*, *pertuzumab* with *trastuzumab* plus *docetaxel*, *pertuzumab* with *trastuzumab*(no chemotherapy), and *pertuzumab* with docetaxel" (Gianni et al. 2012). The treatment combining two mAbs was highly effective than chemotherapy using only one mAb. Treatment with "*pertuzumab* in association with trastuzumab plus docetaxel" demonstrated a considerable enhancement in PCR when compared with trastuzumab plus docetaxel alone.

### 2.6.4 Conjugates of Antibodies and Drugs

"Antibody-drug conjugates (ADCs)" are made up of synthetic connection between recombinant mAb and a cytotoxic drug (Beck et al. 2017). Internalization of the antibody occurs after it binds to a specific antigen on the surface of the cancerous cell. The drug is subsequently delivered into the cell, where it causes cytotoxicity (Fig. 2.4).

T-DM1 is an "ADC" used to cure individuals with "HER2 (+) mBC" which have already been mediated with "*trastuzumab*" plus taxane (individually or in conjunction). EMILIA (NCT00829166) and KATHERINE (NCT01772472) were two clinical trials that looked at their safety and effectiveness (Verma 2012). In the phase 3 EMILIA study, T-DM1 and lapatinib with capecitabine were compared in individuals with "HER2 + mBC" who had earlier been mediated with "*trastuzumab"* and taxane chemotherapeutic agent. T-DM1 therapy substantially increased the PFS up to 10 months compared to *lapatinib* plus capecitabine PFS (6 months), (Verma 2012). In the KATHERINE study, the protection and effectiveness of T-DM1 were investigated in individuals with "HER2+ early BC" who had previously provided with neo-adjuvant treatment with "taxane and *trastuzumab."* Individuals mediated with "T-DM1" had a incomparably better invasive DFS than those treated with *trastuzumab* after an average duration of forty-months.

Another ADC trastuzumab deruxtecan which is also recognized as Ds-8201 is made up of "anti-HER2" immunoglobin and a "topoisomerase inhibitor." It is for adults who had two or more "anti-HER2" therapies in metastatic-context and have advanced or unresectable BC (Beck et al. 2017).




**Fig. 2.4** Mechanism of ADC in breast cancer treatment: an antibody specific for the tumor-associated antigen in conjugation with cytotoxic drug binds to the cancer cell receptor and then internalization and release of cytotoxic drugs occurs inside the cancer cell which leads to the death of cancer cell

### 2.6.5 mTOR Pathways

The mTOR pathway appears to play a considerable position in targeted tumor therapy. In 70% of breast tumors, the PI3K/AKT/mTOR pathway is highly activated, and the kinase proteins discovered along these pathways could be prospective therapeutic targets for BC treatment. the mTOR pathway with the drug "everolimus" in conjunction with "HER-2 or ER inhibitors" is perhaps a hopeful perspective approach to make use of, and restore the "sensitivity of BC cells" to conventional therapies as well as overcome resistance processes that appear to evolve, "when the mTOR pathway" is overactive (Grunt and Mariani 2013). Glaysher et al. discovered that utilizing EGFR and mTOR inhibitors to target breast epithelial cell lines with knocked-in mutations resulted in improved responsiveness to therapeutic drugs. The study investigated the impacts of impeding "mTOR and EGFR" both with the associated drug activity of "sirolimus /ZSTK474 and gefitinib / erlotinib" on the parental cell line, finding a more efficient signaling blockade than with single agents regardless of the "knocked-in mutations in EGF, PI3K, KRAS, BRAF, or AKT" (Glaysher et al. 2014).

### 2.6.6 Receptor Tyrosine Kinase Inhibitors

Basically "Kinase-inhibitors" are tiny molecular compounds that interact with the "ATP-binding region of a tyrosine-kinase-receptor, such as HER2" and inhibit its activity (García-Aranda and Redondo 2017). Lapatinib, also known as Tykerb, is a kinase inhibitor that suppresses growth induced by the EGFR ErbB1 and HER2 pathways. Individuals with LA or mBC who progressed following a standard therapy with taxanes, anthracyclines, or trastuzumab were enrolled in "phase-3 trial" and assess the safety as well as effectiveness of lapatinib in conjunction with "capecitabine. Lapatinib + capecitabine" reduced probability of recurrence by 43%, in comparison to capecitabine alone (Geyer et al. 2006).

A second kinase inhibitor, neratinib or Nerlynx, is approved as a single drug for adjuvant therapy of HER2+ EBC after adjuvant trastuzumab therapy. It is also used with "capecitabine to treat HER2+ mBC" in people who had two or even more anti-HER2 therapies before (Segovia-Mendoza et al. 2015). The "phase-3-trial" ExteNET "NCT00878709" found that individuals which got "*neratinib*" instead of "*Placebo*" following conventional trastuzumab-based adjuvant treatment had substantially lower invasive DFS survival results after an average duration of roughly five years (Martin 2017). Recently tucatinib, also known as Tukysa—another kinase inhibitor recommended by the "FdA" in 2020 for the diagnosis of "$HER2^+$ mBC" in conjunction with trastuzumab and capecitabine. The "HER2CLIMB trial (NCT02614794)" investigated *"tucatinib"* in conjunction with *trastuzumab* as well as *capecitabine* in individuals having "HER2 + MBC" who had earlier been diagnosed with—*pertuzumab, trastuzumab*, and T-DM1. At one year, the *tucatinib* examined group ($n = 410$) had 46% reduced possibility of illness recurrence and

mortality than the one administered with *capecitabine* plus *trastuzumab* alone ($n = 202$) (Murthy et al. 2020).

## 2.7 Function of Immunotherapies in the Diagnosis of Mammary Cancer

Immune system has a multifaceted function to play in cancer detection/prevention, early elimination, and progression. Elimination, equilibrium, and escape are three separate processes of host immune-surveillance and responses described by the "immunoediting" theory (Schreiber et al. 2011). Both innate and acquired immune systems work simultaneously to identify as well as remove cancer during the elimination phase. Few cancerous cells that survived the phase of elimination are thought to gain entry into the phase of equilibrium, in which the adaptive immune responses stop tumor expansion and keep them in a dormant state without eradicating the tumor. Tumor cells develop the capability to avoid immune detection and destruction during the escape phase in many ways (Schreiber et al. 2011). As a result, tumor-immune system evasion is a defining feature of malignancy (Hanahan and Weinberg 2011). Enhancing innate immune systems for cancer has been begun with high-dose interleukin-2 several decades ago, which has shown a sustainable therapeutic advantage for metastatic cancer patients, especially melanoma and renal cell carcinoma (Klapper et al. 2008; Qayoom et al. 2021). Following the discovery of therapeutically meaningful inhibitory routes of T cell activation: the "PD-1/PD-L1 and CTLA-4" there has been substantial upsurge in utilization of immuno-oncology methods (Keir et al. 2007). Immune checkpoint MAB inhibitors that block these pathways have shown to be effective in a range of malignancies, including melanoma, renal cell carcinoma, and NSC lung carcinoma. Furthermore, checkpoint inhibitors have been shown to produce long-lasting therapeutic improvements as well as increased percentage of "patients" living far away from the historic median, as earlier described in standard chemotherapeutic agents.

### 2.7.1 Role of Checkpoint Inhibitors in Immunotherapy

They are regarded as the major effectors of cell-mediated immunity because activated CD8+ (cytotoxic T lymphocytes) identify and kill pathogen-infected or abnormal cells such as tumor cells (Fig. 2.5). T cells, on the other hand, augment immunoglobin reactions via the activity of "Cd4+ [T-helper cells]" as well as augmentation of the anti-body synthesis by B-cells, therefore their stimulation is an important stage in the commencement and control of the immunological responses.

Both antigen-specific-stimulatory signals directing the interaction of "TCR to HLA-II" displayed on cell surface of APCs play a functional part in the activation and maturation of T-cells, according to lymphocyte-activated two-signal model (Fontana and Vance 2011; Mir 2015). At several moments throughout the immune

response, stability of co-stimulatory and suppressive signals, also known as immune checkpoints, regulates the ensuing response, which prevents tissue damage and maintains self-tolerance (Pardoll 2012), and (Buchbinder and Desai 2016). Dysregulated production of inhibiting signals indicates a considerable benefit in the tumor micro-environment, resulting in immune escape, due to their immunosuppressive activities. Combinations of immunological checkpoint receptors and ligands are currently being studied as methods for cancer therapy by reinstating immune systems functionality, either as monotherapies or in combo therapies due to their relationship with lymphocyte activity suppression and consequent energy (Pardoll 2012; Darvin et al. 2018). In particular, all the pathways, i.e., "CTLA4, CD152 and Pd-1, CD279 or Pd-L1, CD274" have illustrated their validity for novel cancer therapy advancement and permitted clinical approval of these two pathways due to their involvement in the immune responses and peripheral tolerance.

T cell stimulation is regulated by additional costimulatory signals including Cd28 and CTLA-4, aside from the T cell communication with HLA-II. In this regard, "CTLA-4 signaling" impedes activation of T-cells, in contrast to CD-28 signaling, that are needed for activation of "T-cell and cytokine production." This is particularly essential in lymphatic nodes where CTLA-4 counteracts possibly auto-reactive T-cells during early activation stages of Cd-4 and Cd-8 cells (Buchbinder and Desai 2016). CD80 and CD86 ligands displayed on activated APCs can stimulate CD28




**Fig. 2.5** (**a**) Attachment of "Pd-L1 to Pd-1" holds T cells from harming cancer cells inside our body. (**b**) Inhabiting the binding "PD-L1 to PD-1" with an "immune checkpoint inhibitor" (anti-PD-L1 or anti-PD-1) permits the T cells to cause death of cancerous cells

and CTLA-4, resulting in T-cell differentiation and proliferation via the formation of growth cytokines or by T-cell receptor signaling proteins dephosphorylation by tyrosine phosphatases when the CD28:CD80/CD86 ratio is high (Bell et al. 2018; Guntermann and Alexander 2002). Because "CTLA-4" has a strong affinity for CD80/86, it promotes immunosuppression by vying for Cd-28 and driving Cd80/86 removal from APCs surfaces (Seidel et al. 2018). As a result, "CTLA-4 inhibitors" can avoid T-cell depletion as well as increase the anti-tumor T-cell responses by limiting the association of "CTLA-4 and Cd80/86 ligands" (Fellner 2012). Although *ipilimumab* has been shown to improve lifespan in individuals with complex tumors, significant immuno-controlled complications, a hefty price tag, and limited response rates (varying from 4% to 16%) remained the main barriers to its usage (Fellner 2012).

"Pd-1" however, is primarily associated in the regulation of formerly "activated T-cells" in subsequent phases of an "immune response" primarily in tissues and cancers (Pardoll 2012; Buchbinder and Desai 2016). In T-cells with the "exhausted phenotype" membrane receptor expression can momentarily generated in "activated Cd8 T-cells" NK T-cells or myeloid-cells after T-cell receptor stimulation and activation by cytokines and interleukins is constitutive. When "PD-1" binds its ligand, PD-L1 enhances "T-cell-receptor proximal signal components dephosphorylation and inhibits signaling pathways controlled by protein kinases such as PTEN, CK2, PI3K/AKT, and RAS/MEK/ERK, T-cell generation, survival, chemokine synthesis, and rest repressor activities are-all reduced. Therefore, "checkpoint inhibitors" have ability to reinstate anticancer immune-response as well as increase "immune-mediated" tumor cell clearance by disturbing the link between "Pd-1 and Pd-L1"(Darvin et al. 2018). Even though *nivolumab* alone and in combination with *ipilimumab* enhances response rates completely in patients with metastatic-melanoma as compared to *ipilimumab* alone, response rates to "PD-1/PD-L1" inhabiting treatments hardly vary from 20–38% across tumor types, implying that these treatments are ineffective for the vast majority of advanced-stage patients (Garcia-Aranda and Redondo 2019). Although immune-related side effects and poor response rates in some patients with cancer, "CTLA4, and PD-1/PD-L1 inhibitors" have been shown to improve strong and long-lasting anti-tumor response and extend the average lifespan of patients with advanced cancer.

### 2.7.2 Breast Cancer Immunogenicity

Unlike nephroma and melanoma, which possess the major susceptivity for biological therapies, BC has not been generally thought to be immunogenic. Furthermore, immuno-suppressive substances are released by the tumor microenvironment in BC, which makes antigen presentation complex and harms the immune response (Mittendorf et al. 2007; Mehraj et al. 2021a, 2021b). It is also feasible to avoid immunological damage by suppressing autogenous immune-check-points which ordinarily end body's defense following the activation of antigen.

Despite having a minor impact on prime cancer growth, the defense system appears to be successful in avoiding BC metastases (Bidwell et al. 2012). With proper immune activation, it appears that every tumor can be immunogenic. The immune system appears to have played a key role in reaction to "monoclonal antibodies and tyrosine kinase inhibitors" and apart of data suggests it may also play a role in responses to endocrine therapy. Trastuzumab's mode of activity has traditionally been linked with antibody-dependent cellular cytotoxicity (Musolino et al. 2008; Tamura et al. 2011). As a result, a functional immune system is required for complete tumor response following molecularly targeted treatments, leading the way toward fundamentally novel regimens combining a targeted and immunological approach (Rakhra et al. 2010). To boost the anti-tumor responses, mAbs targeting "antigen tumor targets or immune-regulatory" substances, cell-mediated treatments such as "adoptive transfer of ex vivo-activated T and NK cells" or T-reg cell inhibition could be used.

## 2.8 Surgical Treatment of Breast Cancer

During surgery, tumor and some normal tissues in the nearby area are removed. Lumpectomy (excision of the lump solely) or mastectomy (surgical excision of the whole breast) is done based on the stage and type of malignancy. The surgeon must confirm that the margins of the tissues removed in the surgery are free of malignancy, showing that cancer has been entirely excised, according to standard procedure. Additional surgeries to excise more tissue might be required if the excised tissues do not provide clear margins. A portion of the pectoralis major, the front chest wall's principal muscle, may need to be removed in some cases. Breast cancer surgical treatment has evolved significantly over time. Previously, therapy required significant surgery and a lengthy hospital stay; however, it is now typically carried out an out-patient operation with rapid improvement (Lowery et al. 2012). Surgical treatment aims to improve local management, avoid locoregional relapse, and prolong survival. Simple mastectomy or reconstructed, with "primary or delayed" or "breast conservation treatment (BCT)" with or with-out the application of angioplasty procedures, are the various surgical methods for the treatment of breast tumors (Fig. 2.6) (Lowery et al. 2012).

### 2.8.1 Breast-Conserving-Therapy (BCT)

Breast-conserving-therapy may be diagnosed with a basic "broad excision" or varying levels of onco-plastic. BCT is regarded as an absolute surgical treatment for subset of BC patients and is nosologically acceptable (Hartmann-Johnsen et al. 2015; Mansell et al. 2017). BCT comprises lumpectomy which is followed by adjuvant radiation treatment to the whole breast. To perform BCT, tumor is removed with excellent cosmetic results and negative-margins, the individual should allow to receive radiation, and the breast should be suitable for the follow-up imaging to




**Fig. 2.6** Different types of surgical treatments in breast cancer treatment

swiftly identify local recurrence, a negative margin signifies "NO ink on the tumor" (Moran et al. 2014). Greater margin clearance does not enhance local-control in metastatic mammary cancer which is not necessary for "BC." If negative margins can be achieved with acceptable cosmetic results, lumpectomies can be performed regardless of the size of the tumor (Houssami et al. 2014). Females with large tumors compared to their breast size may benefit from neo-adjuvant their malignancies. "Bilateral-mastectomy" is examined in individuals with "BRCA1/2 mutations" as the chance of developing a new primary BC in the 20 years after diagnosis might vary from 26 to 40 percent, based on the age of initiation of first cancer, oophorectomy, and administration of endocrine therapy (Kuchenbaecker et al. 2017).

The imaging techniques commonly used to evaluate patients for BCT are clinical examination, mammograms, and diagnostic ultrasonography. According to "population-based research" of 1984, females with "DCIS and stages I and II" aggressive malignancies found that 88% of those who attempted BCT were effective. Because many females were switched to mastectomy without attempting re-excision, this is likely an underestimation of the proportion of females suitable for BCT (Morrow et al. 2009). The number of individuals who receive BCT and the number of individuals who only require one surgical treatment varies depending on the surgeon's skill. A study of surgical margins and treatment success rates in the United States demonstrated this (Morrow et al. 2017). It was a population-based study with roughly 7000 potential individuals, which was later decreased to 3279 in the analytical cohort. A total of 342 of the 488 surgeons who treated these individuals completed a survey on margins following lumpectomy. When compared to those

treating 20 or fewer instances per year, those treating greater than 50 cases per year were substantially more probable to state a "no tumor on ink" sides as acceptable.

### 2.8.2 Mastectomy

A mastectomy is a medical surgery in which a whole or part of the breast is clear away. It originated from Greek word masts, which means "woman's breast" and the Latin word ectomia, which means "excision of." The greater part of patients undergoing this surgery has the choice of "total mastectomy or simple mastectomy, skin-sparing mastectomy" as well as "nipple areolar-sparing mastectomy." During a total-mastectomy, the breast parenchyma, nipple-areolar complex, and extra skin from the breast wall are all removed leaving only enough skin to cover the incision. This is frequently utilized whenever a person is not going through an immediate repair. The "skin-sparing mastectomy" which involves removing both "breast parenchyma and nipple-areolar" complexes, maintaining skin as a suitable-envelope for implantation of the "tissue expander or implant or donor flap, allows for rapid regeneration." The oncological efficacy of "skin-sparing-mastectomy" has been shown to be more effective against cancer than with basic mastectomy, with local recurrence of rate of 6% (Meretoja et al. 2007; Carlson et al. 2003; Lanitis et al. 2010). "The skin envelope and nipple-areolar" complex is preserved after a "nipple-areolar-sparing mastectomy." The first employed as a preventative measure, but it is currently being utilized more frequently in individuals having aggressive cancer. Recurrence rates of 2–5% have been observed locally, having an average duration of "2–5 years" (Moo et al. 2016; De Alcantara Filho et al. 2011). Patients must be cautiously chosen for this operation till long-term oncological safety has been proven, as a majority of the data come from single-institution retrospective studies with minimal follow-up.

### 2.8.3 Dissection of the Axillary Lymph Nodes

The cancer-specialist eliminates a clump of lymph nodes from underneath the armpit in an "axillary lymph node dissection." Axillary lymph node dissection (ALND) is frequently utilized in breast tumor surgery as a diagnostic and predictive marker. ALND is suggested for women with invasive BC as a component of their primary surgical therapy. It is a critical component in the surgical treatment of BC. Pathologic evaluation of the excised lymph nodes provides data that aids in determining the disease's pathological stage and is an important aspect of BC therapy (Le et al. 2016). ALND may improve the whole survival of women with BC by controlling regional node disease.

### 2.8.4 Sentinel Node Biopsy

Considering the first stage BC, SLNB is a comfortable and reliable procedure. The SLNB has turned into the standard process for assessing metastatic progression to the lymph node area (Lyman et al. 2005; McMasters et al. 2000). The "sentinel lymph node" is considered as the primary lymph gland in the "lymphatic basin" to acquire outflow from an anatomic area and is immunologically accountable for that area (Faries et al. 2000). Because of its reduced "false-negative rate" between 5% and 10% and remarkable sensitivity-value of around 90–95 percent in cancer observation in the lymphatic node region, this least invasive procedure has become the gold standard (Veronesi et al. 2010). At present, the SLNB has surpassed the ALND in axilla staging due to the exactness and low morbidity and invasion for the clinical node-negative disease.

## 2.9 Summary

Breast carcinoma is considered one of the most challenging diseases with a significant death rate. On the basis of hormonal expression and growth factor receptors, it is divided into a few primary molecular subtypes. Significant progress has been achieved in the discovery of novel treatments to treat BC over the past few years. With a comprehensive understanding of physiological variability of BC, a more successful and customized therapeutic strategy has been developed. Improvements in cancer risk prediction, precise prognosis evaluation, and innovative treatments in the adjuvant and neo-adjuvant settings, including immune-therapies or antibody-drug conjugates (ADCs), have all contributed to a steady advancement in therapy. Chemotherapeutic combinations comprising *anthracyclines* and *taxanes* have shown effective results in the treatment of BC. Moreover, the efficacy of hormonal therapies like "anti-HER2 MABs" possesses verified possibility along with a great significance of "molecular targeting in breast cancer" management. Checkpoint blockade has developed as an exciting treatment option for BC, particularly TNBC. Following BCT, radiotherapy reduces death rate and relapse. Most breast tumors with physiologically negative ALNs are candidates for SLNB, which eliminates the arm inflammation and discomfort involved in ALND. Individuals having BC are surviving much more than ever, thanks to the deployment of such treatments that leads to lower mortality. To conclude, it is evident that BC treatment is a subject that is continually evolving, with advancements being made all the time.

## 2.10 Further Readings

For more insights about the topic we would suggest detailed findings from the books of (Mir 2022) https://doi.org/10.1016/C2021-0-02565-7, https://doi.org/10.1016/C2022-0-00074-X (Mir 2021) https://doi.org/10.52305/WXJL6770, from cancer.net website, https://www.cancer.net/cancer-types/breast-cancer/types-treatment

For diagrammatic illustrations, descriptive tables (lazzeroni, 2012) http://www.eurekaselect.com/article/49928

https://www.researchgate.net/publication/342829505_Molecular_Complexity_of_Lymphovascular_Invasion_The_Role_of_Cell_Migration_in_Breast_Cancer_as_a_Prototype/figures?lo=1

See video links on over all status of Cancer, its various types, current new treatment possible options available

https://www.sciencedirect.com/science/article/pii/S205970292032278X; https://youtu.be/wIsdjfwPUxY
https://youtu.be/SVjJt984PlU

## References

Anampa J, Makower D, Sparano JA (2015) Progress in adjuvant chemotherapy for breast cancer: an overview. Br J Cancer 13:195

Bamett G, Wilkinson J, Moody AM et al (2009) A randomized controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. Radiother Oncol 92:34

Begg AC, Stewart F, Vens C (2011) Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11:239–253

Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E et al (2016) Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III ideal trial *breast cancer symposium.* San Antonio, TX, S-04: p2-09-01

Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119

Bidwell BN, Slaney C, Withana NP, Forster S, Cao Y, Loi S et al (2012) Silencing of irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18:1224–1231

Bell RB, Fernandes RF, Bifulco CB, Leidner R, Weinberg A, Fox BA (2018) 15 immunotherapy. In: Oral, head and neck oncology and reconstructive surgery. Elsevier, St. Louis, pp 314–340

Buchbinder EI, Desai A (2016) Ctla-4 and pd-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39:98–106

Darvin PT, Toor SM, Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50:1

Bese NS, Munshi A, Budrukkar A, Elzawawy A, Perez CA (2008) Breast radiation therapy guideline implementation in low- and middle-income countries. Cancer 113:2305–2314

Beck A, Goetsch L, Dumontet C, Corvaïa N (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16:315–337

Band PR (2010) The birth of the subspecialty of medical oncology and examples of its early scientific foundations. J Clin Oncol 1:3653–3658

Bland KI, Copeland E (2009) Comprehensive management of benign and malignant diseases. Elsevier, Philadelphia

Borghero YO, Salehpour M, McNeese MD et al (2007) Multileaf field-in-field forward-planned intensity-modulated dose compensation for whole-breast irradiation is associated with reduced contralateral breast dose: a phantom model comparison. Radiother Oncol 83(3):324–328

Braunstein LZ, Taghian A, Niemierko A et al (2017) Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat 161(1):173–179

Citron ML, Berry D, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial c9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431–1439

Coombes RC, Hall E, Gibson LJ, Intergroup Exemestane Study et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 11:1081–1092

Carlson GW, Styblo T, Lyles RH, Jones G, Murray DR, Staley CA et al (2003) The use of skin sparing mastectomy in the treatment of breast cancer: the Emory experience. Surg Oncol 12: 265–269

Dickler A (2009) Axxent electronic brachytherapy: a new device for delivering brachytherapy to the breast. Nat Clin Pract Oncol 6:138–142

De Alcantara Filho P, Capko D, Barry JM, Morrow M, Pusic A, Sacchini VS (2011) Nipple-sparing mastectomy for breast cancer and risk-reducing surgery: the memorial Sloan-Kettering cancer center experience. Ann Surg Oncol 18:3117–3122

Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241

Faries MB, Bedrosian I, Reynolds C et al (2000) Active macromolecule uptake by lymph node antigen-presenting cells: a novel mechanism in determining sentinel lymph node status. Ann Surg Oncol 7:98–105

Fellner C (2012) Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. Pharm Ther 37(9):503–530

Fontana MF, Vance RE (2011) Two signal models in innate immunity. Immunol Rev 243:26–39

Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685

Franklin MC, Carey K, Vajdos FF et al (2004) Insights into ErbB signaling from the structure of the erbb2-pertuzumab complex. Cancer Cell 5:317–328

García-Aranda M, Redondo M (2017) Protein kinase targets in breast cancer. Int J Mol Sci 18:2543

García Rodríguez J, Colmenero CG, Soler RC, Sánchez IO (2010) Five years survival of women diagnosed with breast cancer during the period 1997-1999 in Toledo-Centro and Mancha Area, Spain. Rev Esp Salud Publica 86:843

Garcia-Aranda M, Redondo M (2019) Targeting protein kinases to enhance the response to anti-pd-1/pd-l1 immunotherapy. Int J Mol Sci 20(9):2296

Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

Guntermann C, Alexander DR (2002) Ctla-4 suppresses proximal tcr signaling in resting human cd4+ T cells by inhibiting zap-70 tyr319 phosphorylation: a potential role for tyrosine phosphatases. J Immunol 168:4420–4429

Gennari A, Sormani M, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P et al (2008) Her2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100:14–20

Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with her2-positive early breast cancer: a 4-year follow-up of a randomized controlled trial. Lancet Oncol 236:1016

Glaysher S, Bolton L, Johnson P, Torrance C, Cree IA (2014) The activity of EGFR, mTOR, and PI3k inhibitors in an isogenic breast cell line model. BMC Res Notes 7:397

Grunt TW, Mariani G (2013) Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3k/AKT/mTOR signaling. Curr Cancer Drug Targets 13:188–204

Gianni L, Pienkowski T, Im Y-H et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (neosphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25–32

Gianni L, Romieu G, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O et al (2013) AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31:1719–1725

Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 32:2078–2099

Peto R, Davies C, Godwin J, Gray R, Pan HC et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444

Howell A, Cuzick J, Baum M et al (2005) Results of the atac (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years & 39;djuvant treatment for breast cancer. Lancet 1:60–62

Hanahan D, Weinberg R (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

Hartmann-Johnsen OJ, Kåresen R, Schlichting E, Nygard JF (2015) Survival is better after breast conserving therapy than mastectomy for early stage breast cancer: a registry-based follow-up study of Norwegian women primary operated between 1998 and 2008. Ann Surg Oncol 22: 3836–3845

Herrick JS, Neill CJ, Rosser PF (2008) A comprehensive clinical 3-dimensional dosimetric analysis of forward planned IMRT and conventional wedge planned wedged techniques for intact breast radiotherapy. Med Dosim 33:62–70

Houssami N, Macaskill P, Marinovich ML, Morrow M (2014) The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol 21:717–730

Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461: 1071–1078

Jakesz R, Jonat W, Gnant M, ABCSG and the GABG et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years & 39; adjuvant tamoxifen: combined results of abcsg trial 8 and arno 95 trial. Lancet 6:455–462

Jankowitz RC, Davidson N (2013) Adjuvant endocrine therapy for breast cancer: how long is long enough. Oncology 27:1210–1216

Jones S, Holmes F, Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. J Clin Oncol 27:1177–1183

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2007) Pd-1 and its ligands in t-cell immunity. Curr Opin Immunol 19:309–314

Klapper JA, Downey S, Smith FO et al (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the national cancer institute between 1986 and 2006. Cancer 113: 293–301

Keisch M, Vicini F, Kuske R et al (2003) Initial clinical experience with the mammo site breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 55(2):289–293

Kuchenbaecker KB, Hopper J, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–2416

Lowery AJ, Kell M, Glynn RW, Kerin MJ, Sweeney KJ (2012) Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 133:831–841

Lyman GH, Giuliano A, Somerfield MR et al (2005) American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703–7720

Lanitis S, Tekkis P, Sgourakis G, Dimopoulos N, Al Mufti R, Hadjiminas DJ (2010) Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. Ann Surg 251:632–639

Mamounas EP (2003) Neoadjuvant chemotherapy for operable breast cancer: is this the future? Clin Breast Cancer Suppl 1:S10–S19. https://doi.org/10.3816/cbc.2003.s.010

McGale P, Taylor C, Correa C et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383:2127–2135

Mehraj U, Dar A, Wani NA, Mir MA (2021a) Tumor microenvironment promotes breast cancer chemoresistance. Cancer Chemother Pharmacol 9:1–2

Mehraj U, Qayoom H, Mir MA (2021b) Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives. Breast Cancer 28:539–555

Mir MA, Qayoom H, Mehraj U, Nisar S, Bhat B, Wani NA (2020) Targeting different pathways using novel combination therapy in triple negative breast cancer. Curr Cancer Drug Targets 20: 586–602

Mittendorf EA, Peoples G, Singletary SE (2007) Breast cancer vaccines: promise for the future or pipe dream. Cancer 110:1677–1686

Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G et al (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26(11):1789–1796

Martin M, Holmes F, Ejlertsen B, ExteNET Study Group et al (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5- year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688–1700

Mir MA (2015) Introduction to costimulation and costimulatory molecules. In: Developing costimulatory molecules for immunotherapy of diseases. Elsevier Academic Press, Cambridge, pp 1–299. https://doi.org/10.1016/c2014-0-02898-5

Murthy RK, Loi S, Okines A et al (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382:597–609

Mansell J, Weiler-Mithoff E, Stallard S, Doughty JC, Mallon E, Romics L (2017) Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. Breast 32:179–185

Moran MS, Schnitt S, Giuliano AE, Harris JR, Khan SA, Horton J et al (2014) Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 32:1507–1515

Masoud V, Pagès G (2017) New challenges to fight against resistance. World J Clin Oncol 8:120–134

McMasters KM, Tuttle T, Carlson DJ et al (2000) Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18:2560–2566

McPhail S, Johnson S, Greenberg D, Peake M, Rous B (2015) Stage at diagnosis and early mortality from cancer in England. Br J Cancer 112:s108

Mamtani A, Barrio A, King TA, Van Zee KJ, Plitas G, Pilewskie M et al (2016) How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol 23:3467–3474
Meretoja TJ, Rasia S, Von Smitten KA, Asko-Seljavaara SL, Kuokkanen HO, Jahkola TA (2007) Late results of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg 94:1120–1125
Morrow M, Abrahamse P, Hofer TP, Ward KC, Hamilton AS, Kurian AW (2017) Trends in reoperation after initial lumpectomy for breast cancer: addressing overtreatment in surgical management. JAMA Oncol 3:1352–1375
Morrow M, Jagsi R, Alderman AK, Griggs JJ, Hawley ST, Hamilton AS et al (2009) Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA 302:1551–1561
Moo TA, Pinchinat T, Mays S, Landers A, Christos P, Alabdulkareem H et al (2016) Oncologic outcomes after nipple-sparing mastectomy. Ann Surg Oncol 23:3221–3225
Mieog JS, van der Hage JA, Van de Velde CJ (2007) Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94:1189–1200
Nami B, Wang Z (2017) Her2 in breast cancer stemness: a negative feedback loop towards trastuzumab resistance. Cancers 9:40
Nelson J, Beitsch P, Vicini F et al (2009) Four year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. Am J Surg 198(1):83–91
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Herceptin adjuvant (hera)trial study team. Trastuzumab after adjuvant chemotherapy in her2-positive breast cancer. N Engl J Med 353:1659–1672
Press MF, Sauter G, Buyse M, Bernstein L, Guzman R et al (2011) Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 29:859–867
Qayoom H, Wani N, Alshehri B, Mir MA (2021) An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer. Future Oncol 17:4185–4206
Qayoom H et al (2022) Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study. Med Oncol 39:158. https://doi.org/10.1007/s12032-022-01779-9
Romond E, Perez E, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer. N Engl J Med 353:1673–1684
Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A et al (2010) Cd4(+) t cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18:485–498
Schlembach PJ, Buchholz TA, Ross MI et al (2001) Relationship of sentinel and axillary level I and II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys 51(3):671–678
Scanderbeg J, Yashar C, Rice R et al (2009) Clinical implementation of a new brachytherapy device for partial breast irradiation. Radiother Oncol 90:3642
Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–1671
Schreiber RD, Old L, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565–1570
Segovia-Mendoza M, González-González M, Barrera D, Díaz L, García-Becerra R (2015) Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the

treatment of her2-positive breast cancer: preclinical and clinical evidence. Am J Cancer Res 5: 2531–2561

Seidel JA, Otsuka A et al (2018) Anti-pd-1 and anti-ctla-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86

Slamon D, Eiermann W, Robert N, Breast Cancer International Research Group et al (2011) Adjuvant trastuzumab in her2-positive breast cancer. N Engl J Med 365:1273–1228

Smith I, Yardley D, Burris H et al (2017) Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized phase III femara versus anastrozole clinical evaluation (face) trial. J Clin Oncol 1:1041–1048

Sofi S, Mehraj U, Qayoom H, Aisha S, Almilaibary A, Alkhanani M et al (2022) Targeting cyclin-dependent kinase 1 (cdk1) in cancer: molecular docking and dynamic simulations of potential cdk1 inhibitors. Med Oncol 39:1–15

Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP et al (2013) Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 31:3197–3204

Thürlimann B, Keshaviah A, Coates AS, Breast International Group (BIG) 1-98 Collaborative Group et al (2006) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 18:2200

Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K et al (2011) Fcγr2a and 3a polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with her2-positive breast cancer. Ann Oncol 22:1302–1307

Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227–1232

Vrieling C, Werkhoven EV, Maingon P et al (2017) Prognostic factors for local control in breast cancer after long-term follow-up in the eortc boost vs no boost trial: a randomized clinical trial. JAMA Oncol 3:42–48

Van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol 19:4224–4237

Verma S, Miles D, Gianni L, EMILIA Study Group et al (2012) Trastuzumab emtansine for her2-positive advanced breast cancer. N Engl J Med 367:1783–1791

Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ et al (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295(14):1658–1657

Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339(18):1056

Le VH, Brant K, Blackhurst DW et al (2016) The impact of the American College of Surgeons Oncology Group (ACOSOG) z0011 trial: an institutional review. Breast 29:117–119

Veronesi U, Viale G, Paganelli G et al (2010) Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg Oncol 251(4):595–600